$CVKD
Cadrenal Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000121390024066107 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.212M
YoY Change
% of Gross Profit
Research & Development $784.6K $1.254M
YoY Change 221.64% 1244.02%
% of Gross Profit
Depreciation & Amortization $407.00 $470.00
YoY Change -31.83% -21.27%
% of Gross Profit
Operating Expenses $2.460M $2.467M
YoY Change 115.3% 140.37%
Operating Profit -$2.460M -$2.467M
YoY Change 115.3% 140.37%
Interest Expense $73.64K
YoY Change
% of Operating Profit
Other Income/Expense, Net $52.13K $73.64K
YoY Change -50.89% 217.73%
Pretax Income -$2.393M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.408M -$2.393M
YoY Change 132.31% 138.58%
Net Earnings / Revenue
Basic Earnings Per Share -$2.18 -$0.15
Diluted Earnings Per Share -$2.18 -$0.15
COMMON SHARES
Basic Shares Outstanding 16.01M shares 16.01M shares
Diluted Shares Outstanding 1.104M shares 16.01M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.037M
YoY Change
Cash & Equivalents $4.364M $5.037M
Short-Term Investments
Other Short-Term Assets $406.3K
YoY Change
Inventory
Prepaid Expenses $191.7K $234.9K
Receivables
Other Receivables
Total Short-Term Assets $4.672M $5.444M
YoY Change -49.64% 54.68%
LONG-TERM ASSETS
Property, Plant & Equipment $814.00 $1.220K
YoY Change -71.78% -64.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.792K $3.792K
YoY Change 0.0% 0.0%
Total Long-Term Assets $6.803K $13.67K
YoY Change -79.74% -65.74%
TOTAL ASSETS
Total Short-Term Assets $4.672M $5.444M
Total Long-Term Assets $6.803K $13.67K
Total Assets $4.679M $5.457M
YoY Change -49.75% 53.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $496.8K $759.5K
YoY Change 250.72% 872.01%
Accrued Expenses $767.9K $696.6K
YoY Change 93.46% 156.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.267M $1.465M
YoY Change 124.81% 291.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.267M $1.465M
Total Long-Term Liabilities $0.00
Total Liabilities $1.267M $1.465M
YoY Change 123.92% 282.38%
SHAREHOLDERS EQUITY
Retained Earnings -$21.54M -$19.13M
YoY Change 54.63% 48.38%
Common Stock $1.234K $23.12M
YoY Change -90.52% 197135.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.412M $3.992M
YoY Change
Total Liabilities & Shareholders Equity $4.679M $5.457M
YoY Change -49.75% 53.33%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$2.408M -$2.393M
YoY Change 132.31% 138.58%
Depreciation, Depletion And Amortization $407.00 $470.00
YoY Change -31.83% -21.27%
Cash From Operating Activities -$1.529M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.529M
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash -1.529M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$1.529M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11252903 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41596
dei Entity Registrant Name
EntityRegistrantName
CADRENAL THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0860746
dei Entity Address Address Line1
EntityAddressAddressLine1
822 A1A North
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 306
dei Entity Address City Or Town
EntityAddressCityOrTown
Ponte Vedra
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32082
dei City Area Code
CityAreaCode
(904)
dei Local Phone Number
LocalPhoneNumber
300-0701
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CVKD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16008469 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5037174 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8402500 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234946 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
89673 usd
CY2024Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
171384 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
5443504 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8492173 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1220 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2287 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8655 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20998 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3792 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3792 usd
CY2024Q2 us-gaap Assets
Assets
5457171 usd
CY2023Q4 us-gaap Assets
Assets
8519250 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
759518 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
167319 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
696603 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
638206 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8796 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21350 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1464917 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
826875 usd
CY2024Q2 us-gaap Liabilities
Liabilities
1464917 usd
CY2023Q4 us-gaap Liabilities
Liabilities
826875 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7500000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7500000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16008469 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16008469 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13022754 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13022754 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
16008 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
13022 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
23103931 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
22750768 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19127685 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15071415 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3992254 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7692375 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5457171 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8519250 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1212437 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
784623 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2338430 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1749356 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1253711 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
240957 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1882736 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3476274 usd
CY2024Q2 us-gaap Depreciation
Depreciation
470 usd
CY2023Q2 us-gaap Depreciation
Depreciation
597 usd
us-gaap Depreciation
Depreciation
1067 usd
us-gaap Depreciation
Depreciation
786 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
2466618 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1026177 usd
us-gaap Operating Expenses
OperatingExpenses
4222233 usd
us-gaap Operating Expenses
OperatingExpenses
5226416 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2466618 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1026177 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4222233 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5226416 usd
CY2024Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
73636 usd
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
23176 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
165963 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
23176 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
3534 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13567 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
216095 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-740139 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
73636 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23176 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
165963 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-950159 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2392982 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1003001 usd
us-gaap Net Income Loss
NetIncomeLoss
-4056270 usd
us-gaap Net Income Loss
NetIncomeLoss
-6176575 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16008469 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11722754 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16008469 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11252903 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6192116 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
193120 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2392982 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3992254 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7692375 usd
cvkd Stock Issued During Period Value Issuance Of Common Shares From Exercise Of Prefunded Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonSharesFromExerciseOfPrefundedWarrants
298 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
355851 usd
us-gaap Net Income Loss
NetIncomeLoss
-4056270 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3992254 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4065262 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
113661 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1003001 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3175922 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5551150 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5408575 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1140700 usd
cvkd Adjustmentsto Additional Paidin Capital Derecognitionofderivativeliabilities
AdjustmentstoAdditionalPaidinCapitalDerecognitionofderivativeliabilities
4596039 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
250000 usd
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
3000000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
108276 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
400057 usd
us-gaap Net Income Loss
NetIncomeLoss
-6176575 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3175922 usd
us-gaap Net Income Loss
NetIncomeLoss
-4056270 usd
us-gaap Net Income Loss
NetIncomeLoss
-6176575 usd
us-gaap Depreciation
Depreciation
1067 usd
us-gaap Depreciation
Depreciation
786 usd
us-gaap Share Based Compensation
ShareBasedCompensation
355851 usd
us-gaap Share Based Compensation
ShareBasedCompensation
454195 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13567 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
216095 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-740139 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
211 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-179 usd
cvkd Issuance Of Shares To Settle Asset Purchase Agreement
IssuanceOfSharesToSettleAssetPurchaseAgreement
3000000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
145273 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
212475 usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
171384 usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-672295 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2195 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
592199 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-326758 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
58397 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-591745 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3365624 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2208102 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3253 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3253 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
298 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
250000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
250000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5408575 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
298 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5408575 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3365326 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3197220 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8402500 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32586 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5037174 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3229806 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
1140700 usd
cvkd Derecognition Of Derivative Liabilities
DerecognitionOfDerivativeLiabilities
4596039 usd
cvkd Issuance Of Investor Warrants
IssuanceOfInvestorWarrants
108276 usd
us-gaap Net Income Loss
NetIncomeLoss
-4056270 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
356707 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3365624 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5037174 usd
CY2024Q2 cvkd Workings Capital
WorkingsCapital
3978587 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19127685 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of stock-based awards, deferred tax assets and valuation allowance, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash is maintained at high credit quality financial institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances are insured up to $250,000 at each financial institution. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidate, ability to obtain regulatory approval of its product candidate, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</p>
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3000000 usd
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4920243 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
4920243 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
8287843 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
8287843 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
222014 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
437026 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
596131 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
37563 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38075 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
696603 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
638206 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8655 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20998 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8796 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21350 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
8796 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
21350 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
6839 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
6638 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
13394 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
13274 usd
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
13391 usd
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
13001 usd
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4M
CY2024Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.12 pure
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8928 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8928 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
132 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8796 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7500000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q1 cvkd Warrantto Purchase Common Stock Shares
WarranttoPurchaseCommonStockShares
84000 shares
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7500000 usd
us-gaap Sale Of Stock Percentage Of Ownership After Transaction
SaleOfStockPercentageOfOwnershipAfterTransaction
0.0999 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
7660501 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
2985715 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
4674786 shares
CY2024Q2 cvkd Common Stock Outstanding Percentage
CommonStockOutstandingPercentage
0.20 pure
CY2024Q3 cvkd Reserved Shares Of Common Stock Available For Issuance
ReservedSharesOfCommonStockAvailableForIssuance
0.20 pure
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0443 pure
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M21D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.764 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1175000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.86
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M20D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
105000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1170000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.9
cvkd Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingGranted
P9Y6M29D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2345000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.88
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y10M9D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
868059 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2345000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.88
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.82
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1020238 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P1Y10M24D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
193120 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
167801 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
355851 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
454195 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2392982 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1003001 usd
us-gaap Net Income Loss
NetIncomeLoss
-4056270 usd
us-gaap Net Income Loss
NetIncomeLoss
-6176575 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16008469 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11722754 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16008469 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11252903 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7019786 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1210500 shares
CY2024Q3 cvkd Reserved Shares Of Common Stock Available For Issuance
ReservedSharesOfCommonStockAvailableForIssuance
0.20 pure
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11722754 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16008469 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16008469 shares
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
cvkd Issuance Of Shares To Settle Asset Purchase Agreement
IssuanceOfSharesToSettleAssetPurchaseAgreement
usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
usd
cvkd Derecognition Of Derivative Liabilities
DerecognitionOfDerivativeLiabilities
usd
cvkd Issuance Of Investor Warrants
IssuanceOfInvestorWarrants
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
cvkd Share Based Compensation Arrangement By Share Based Payment Award Options Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
cvkd Weighted Average Remaining Contractual Life Years Exercised
WeightedAverageRemainingContractualLifeYearsExercised
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
cvkd Weighted Average Remaining Contractual Life Years Canceled
WeightedAverageRemainingContractualLifeYearsCanceled
cvkd Share Based Compensation Arrangement By Share Based Payment Award Options Canceled Forfeited Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledForfeitedExpired
usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11252903 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11722754 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16008469 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16008469 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001937993

Files In Submission

Name View Source Status
cvkd-20240630_cal.xml Edgar Link unprocessable
0001213900-24-066107-index-headers.html Edgar Link pending
0001213900-24-066107-index.html Edgar Link pending
0001213900-24-066107.txt Edgar Link pending
0001213900-24-066107-xbrl.zip Edgar Link pending
cvkd-20240630.xsd Edgar Link pending
ea0210248-10q_cadrenal.htm Edgar Link pending
ea021024801ex31-1_cadrenal.htm Edgar Link pending
ea021024801ex31-2_cadrenal.htm Edgar Link pending
ea021024801ex32-1_cadrenal.htm Edgar Link pending
ea021024801ex32-2_cadrenal.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
cvkd-20240630_def.xml Edgar Link unprocessable
cvkd-20240630_lab.xml Edgar Link unprocessable
cvkd-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0210248-10q_cadrenal_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending